CHEMBIO DIAGNOSTIC SYSTEMS, INC., A BIOSYNEX SUBSIDIARY, RECEIVES $1.8 MILLION CARB-X GRANT TO DEVELOP A RAPID DIAGNOSTIC TEST FOR TYPHOID FEVER
Medford, N.Y., USA / Strasbourg, France – February 6, 2026 – Chembio Diagnostic Systems, Inc. (Chembio), a wholly owned subsidiary of Biosynex, a leader in point-of-care (POC) diagnostics, today announced that it has been awarded a $1.8 million grant from CARB-X to support the development of a rapid point-of-care diagnostic test for acute typhoid fever. The test is designed to detect IgA antibodies associated with acute infection caused by Salmonella enterica serovar Typhi (S. Typhi).
Typhoid fever is an acute febrile illness caused by S. Typhi and affects an estimated 11–21 million people globally each year, resulting in approximately 128,000–161,000 deaths annually. The disease remains a major global health challenge, particularly in low-resource settings and endemic regions. Current diagnostic tools are limited, complicating clinical decision-making and delaying appropriate treatment.
This unmet clinical need has been further highlighted by recent World Health Organization (WHO) guidance emphasizing the importance of typhoid vaccination and the parallel need for improved diagnostic tools to enhance disease surveillance, outbreak response, and patient care pathways.
Under the CARB-X award, Chembio will develop a rapid serological test leveraging its proprietary DPP® (Dual Path Platform) technology, targeting two high-performance biomarkers to enable accurate and timely diagnosis of enteric fever. The DPP® Typhoid test will be designed for use with fingerstick whole blood, serum, or plasma samples and is expected to deliver results within minutes when used with the DPP® Micro Reader, a portable reader that applies test-specific algorithms to generate objective results.
“We are honored to receive this funding from CARB-X to advance our innovative rapid diagnostic test for acute typhoid fever,” said Javan Esfandiari, President of Chembio. “Our goal is to enable earlier diagnosis and timely treatment decisions, while helping to reduce inappropriate antibiotic use — thereby minimizing selective pressure that contributes to antimicrobial resistance.”
“This grant underscores the strategic importance of continued innovation within our diagnostics portfolio,” said Larry Abensur, President of Biosynex. “Rapid detection of high-impact infectious diseases remains central to Biosynex’s mission, and we are proud to see Chembio’s platform recognized for its potential contribution to improving global public health. We look forward to advancing this program in close collaboration with CARB-X to deliver meaningful solutions for patients and healthcare systems worldwide.”
Press coverage : https://chembio.com/newsroom
——-
About CARB-X
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global nonprofit partnership that supports early-stage research and development to address the growing threat of antibiotic-resistant bacteria. CARB-X invests in innovative therapeutics, preventatives, and rapid diagnostics targeting the world’s most dangerous resistant pathogens and high-burden infectious syndromes. CARB-X is led by Boston University and funded by a consortium of governments and foundations.
For more information, visit https://carb-x.org/
X (formerly Twitter): @CARB_X
About Chembio Diagnostic Systems, Inc.
Chembio Diagnostic Systems, Inc., a subsidiary of the Biosynex Group, is a leading diagnostics company focused on the development, manufacture, and commercialization of point-of-care tests for infectious diseases. The company’s proprietary DPP® technology platform delivers high-quality, accurate results within minutes, supporting rapid diagnosis and improved patient outcomes worldwide.
For more information, visit www.chembio.com.
About BIOSYNEX
Founded in 2005, the French laboratory BIOSYNEX is a leading health diagnostics group, specializing in rapid tests, biotherapy monitoring, and molecular biology.
As a forward-thinking player in the future of medicine, BIOSYNEX advocates for the improvement of healthcare pathways and offers innovative health solutions to a variety of users, including laboratories, hospitals, doctors, and the general public, aimed at enhancing overall patient care.
Following its significant contribution during the Covid-19 pandemic, BIOSYNEX has gained new international stature in the rapid diagnostics field, partly due to its dynamic external growth strategy. The Group now has research, production, and distribution subsidiaries in the United States, Europe, and Asia, supporting its two business units: BIOSYNEX PHARMACY and BIOSYNEX DIAGNOSTICS.
For the general public: The BIOSYNEX Pharmacy division, specializing in self-diagnostics and family health products, distributes a comprehensive range of well-established and recognized brands across a wide network of pharmacies and parapharmacies, focusing on prevention, diagnostics, and natural care.
For professionals: The BIOSYNEX Diagnostics division, a technology-driven business operating in high-growth sectors, develops and provides laboratories, hospitals, doctors, and nursing homes with in vitro diagnostic medical devices in the form of rapid diagnostic tests (RDTs and POC tests), molecular biology, and point-of-care (POC) products for screening, diagnosis, and prevention.
Based in Illkirch-Graffenstaden, Alsace, the BIOSYNEX Group employs over 500 people and has a presence in 95 countries. The Group achieved a turnover of €93 million in 2023. Listed on Euronext Growth Paris (FR0011005933 ALBIO), BIOSYNEX is eligible for PEA-PME.
For more information, visit www.biosynex.com.
